Alexza raises $45M; Anacor names biotech vet Berns as new CEO;

@FierceBiotech: Novo touts a PhIII hemophilia win as it chases Biogen, Bayer. Story | Follow @FierceBiotech

@JohnCFierce: Bristol-Myers partner Alder Bio looking for $115M IPO haul - clazakizumab and migraine drug ALD403. More | Follow @JohnCFierce

@DamianFierce: Proteon sets out on its own after Novartis waves off a $550M deal. News | Follow @DamianFierce

@GalenMoore: Exact Sciences' at-home test for colon cancer is nearly as effective as a colonoscopy. Read more at Bloomberg | Follow @GalenMoore

> Mountain View, CA-based Alexza Pharmaceuticals has raised $45 million from the sale of notes to institutional investors. Release

> Anacor Pharma named Paul Berns as its new CEO. Berns had been CEO of Allos Therapeutics. Release

Medical Device News

@FierceMedDev: Here's our latest FierceDiagnostics, with news on concussion biomarkers, autism tests and more. Newsletter | Follow @FierceMedDev

@MarkHFierce: A European VC firm is raising $ for a new fund that will target, in part, Dx and device companies. Story | Follow @MarkHFierce

@MichaelGFierce: NASA tech makes space-age microcapsules for cancer drug delivery. More from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: Good news for chocolate lovers: Bacteria in the gut can eat up cocoa and turn it into compounds that help the heart. Article | Follow @EmilyWFierce

> C.R. Bard enrolls first patient in a new U.S. clinical trial of its drug-coated balloon. News

> Augmedix grabs $3.2M for Google Glass-enabled medical records physician tool. More

> Flagging Smiths Medical, soaring pound weigh down Smiths Group earnings. Story

Pharma News

@FiercePharma: Statins and muscle aches are unrelated. Story | Follow @FiercePharma

@TracyStaton: FiercePharma's best-read weekend news: Gilead's hot-selling Sovaldi draws more patent attacks. Article | Follow @TracyStaton

@EricPFierce: New purification plant is part of Novo Nordisk 's $3.7B R&D push. News | Follow @EricPFierce

> Tamiflu study funded by Roche shows lives saved in pandemic. More

> Roche breast cancer drugs Perjeta, Kadcyla are built for speed, report finds. Item

> Medivation, Astellas ask FDA to approve Xtandi for pre-chemo prostate cancer use. Piece

Drug Delivery News

> MedImmune inks licensing deal with Bioasis for brain delivery platform. News

> GenSpera enrolls brain cancer mid-stage trial with 'grenade' delivery. Story

> NASA tech makes space-age microcapsules for cancer drug delivery. Story

> Harvard scientists fold DNA to make cages for drug delivery. Article

> CeloNova wins a U.S. exemption trial for its nano-coated stent. News

> Oral drugs derived from snail venom could offer less invasive pain management. Brief

Diagnostics News

> Waters Corp. will help develop a blood-based biomarker test to predict the risk of premature birth. Story

> SynapDx and the Broad Institute link to use next-gen sequencing for better autism tests. News

> Quanterix diagnostic spotted a key concussion biomarker in blood. Article

> Is diagnostics maker Corgenix looking to sell itself? Story

> For 2014, Trovagene plots multiple ways to expand the reach of its Dx cancer tech. Story

> Federal funding drops are forcing layoffs at the Broad Institute's genome sequencing arm. Brief

Pharma Marketing News

> They're no Coca-Cola, but top biopharma brands Pfizer, Biogen and Merck still worth billions. Report

> Roche's Perjeta proves a fast fave with cancer docs, but Kadcyla's a speed racer. Story

> McKinsey's four drug launch flavors: Good, bad, ugly and misguided. Story

> Pfizer's impressive Prevnar data isn't enough to win billions in adult sales. Analysis

> For once, the FDA writes up pharma for a simple Facebook violation. News

> Probe finds Novartis not guilty of 'undue influence' at Canadian university eye clinic. Brief

Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Combining KSQ's USP1 inhibitor with Merck and AstraZeneca's PARP inhibitor Lynparza was more effective in animal models than either drug on its own.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.